Mira Pharmaceuticals Submits Ketamir-2 Clinical Trial Protocol to FDA
Mira Pharmaceuticals announced the submission of a Phase 2a clinical trial protocol to the U.S. Food and Drug Administration, FDA, for Ketamir-2, the Company's proprietary oral NMDA receptor modulator, in chemotherapy-induced peripheral neuropathy, XIPN.
